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Abstract
Introduction: Immune responses against collagen type II (CII) are crucial for the development of collagen-induced
arthritis (CIA). The aim of the present study was to evaluate and compare the CII-directed T cell and antibody
specificity at different time points in the course of CIA using two mouse strains on the B10 genetic background -
B10.Q, expressing Aq MHC class II molecules, and B10.DR4.Ncf1*/*, expressing human rheumatoid arthritis-associated
MHC II DR4 molecules (DRA*0101/DRB*0401).
Methods: B10.Q and B10.DR4.Ncf1*/* mice were immunized with CII emulsified in adjuvant and development of
CIA was assessed. T cells from draining lymph nodes were restimulated in vitro with CII peptides and interferon-
gamma (IFN-g) levels in culture supernatants were evaluated by ELISA. CII-specific antibody levels in serum samples
were measured by ELISA.
Results: At four different CIA time points we analyzed T cell specificity to the immunodominant CII epitope 259-
273 (CII259-273) and several posttranslationally modified forms of CII259-273 as well as antibody responses to three
B cell immunodominant epitopes on CII (C1, U1, J1). Our data show that CII-specific T and B cell responses increase
dramatically after disease onset in both strains and are sustained during the disease course. Concerning anti-CII
antibody fine specificity, during all investigated stages of CIA the B10.Q mice responded predominantly to the C1
epitope, whereas the B10.DR4.Ncf1*/* mice also recognized the U1 epitope. In the established disease phase, T cell
reactivity toward the galactosylated CII259-273 peptide was similar between the DR4- and the Aq-expressing strains
whereas the response to the non-modified CII peptide was dramatically enhanced in the DR4 mice compared with
the B10.Q. In addition, we show that the difference in the transgenic DR4-restricted T cell specificity to CII259-273
is not dependent on the degree of glycosylation of the collagen used for immunization.
Conclusions: The present study provides important evaluation of CII-specific immune responses at different phases
during CIA development as well as a comparative analysis between two CIA mouse models. We indicate significant
differences in CII T cell and antibody specificities between the two strains and highlight a need for improved
humanized B10.DR4 mouse model for rheumatoid arthritis.
Introduction
Rheumatoid arthritis (RA) is one of the most common
autoimmune diseases that generally affects peripheral
joints and causes significant physical disability in around
1% of the human population worldwide. In spite of inten-
sive investigation during the last decades RA etiology and
pathogenesis are still unclear. Research with RA patients
often faces impediments due to ethical reasons, complex-
ity of affecting environmental factors and applied thera-
peutics. Thus, a standard approach to study disease
mechanisms and causative agents is the utilization of ani-
mal models. A widely accepted model for RA is collagen
type II-induced arthritis (CIA) in mice. The disease can
be triggered in genetically susceptible strains bearing cer-
tain major histocompatibility complex class II (MHC II)
haplotypes (H-2q or H-2r) as well as in transgenic mice,
expressing HLA-DR4 or DR1 RA-associated alleles [1-4].
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CIA development depends on both T and B cell immune
responses to collagen type II (CII) - the major constituent
of joint cartilage, which is the main site of inflammation
in CIA and also RA. Moreover, CII-specific T cell [5-7]
and humoral [8,9] immunity has been detected in RA
patients and hence CII is considered as a candidate auto-
antigen in RA pathogenesis.
Our group and others have extensively studied CII-
directed immunity using the CIA model. We have identi-
fied a T cell immunodominant epitope from collagen
type II (CII259-273) that plays a major role in CIA devel-
opment in mice with H-2q haplotype [10]. Subsequently,
it was shown that this epitope also binds to human DR4
and DR1 molecules, associated with RA [11,12] and
immunity to CII259-273 was detected also in RA patients
[5,6,13]. Interestingly, the CII259-273 epitope could be
posttranslationally modified (at position 264 and 270) by
lysine hydroxylation and glycosylation. T cell responses
to CII259-273 and its posttranslationally modified forms
have been intensively studied in H-2q, as well as in DR-
transgenic mice. So far, however, little is known about
the magnitude and specificity of CII-directed T cell
immunity over arthritis time course. It is unclear whether
T cells display constant specificity to a certain form
(native or posttranslationally modified) of the CII259-273
epitope or if T cell specificity shifts at different time
points during disease development. Therefore, one of the
main aims of the present study was to characterize the
CII-specific T cell response in CIA over time analyzing
four general stages of disease course: 1) the initial phase
of CIA with no visible signs of disease, 2) the stage when
joint inflammation become apparent, that is, disease
onset, 3) the stage of established disease, and 4) the
chronic phase of CIA. Two different mouse strains were
used for this evaluation - B10.Q strain, expressing H-2q
MHC II haplotype on B10 genetic background, and a
humanized transgenic strain, denoted as B10.DR4.Ncf1*/*,
that expresses HLA-DR4 instead of mouse MHC II mole-
cules on the same genetic background. The study of CII
immunity in these two strains enables comparison
between a classical mouse strain used in arthritis research
and the recently developed transgenic strain that resem-
bles the human situation more closely by expressing
one of the most common HLA alleles in RA patients
(HLA-DRB1*0401). In addition, a second aim of our
study was to investigate the anti-CII antibody levels over
the disease course and compare the response between
the B10.Q and B10.DR4.Ncf1*/* strain. Regarding the
humoral response with significance for development of
CIA and RA, several conserved epitopes from CII have
been defined [14-16]. Research in mouse models indi-
cated that antibodies to U1, C1 and J1 CII epitopes are
arthritogenic and their levels correlate with development
of chronic arthritis [17,18]. Thus, in order to evaluate
anti-CII antibody fine specificity in B10.Q and DR4-trans-
genic mice we investigated the levels of C1, U1 and J1 epi-
tope-specific antibodies. We found notable differences
between B10.Q and DR4-transgenic mice regarding both
humoral and T cell CII fine specificity. The majority of
anti-CII antibodies in the two strains recognized the C1
epitope but in DR4-transgenic mice there was also sus-
tained response to the U1 epitope. Interestingly, in general,
anti-C1 antibody levels showed tendency for correlation
with disease development while anti-U1 antibodies kept
constant levels during CIA. T cell specificity also differed -
in B10.Q mice there was predominant response to the gly-
cosylated form of the CII259-273 epitope while in B10.
DR4.Ncf1*/* mice immunodominant was the native and
the hydroxylated form of the epitope. We did not observe
a shift in dominant epitope specificity at different stages of
disease development in both mouse strains but the magni-
tude of T cell and antibody response showed dramatic
increase at the acute stage of CIA.
Materials and methods
Antigens
Rat CII (rCII) was extracted from Swarm chondrosarcoma
by limited pepsin digestion [19]. Human CII (huCII) was
derived from hip joints and purified as previously described
[19]. Both rCII and huCII proteins were dissolved in 0.1 M
acetic acid and stored at 4°C. Three synthetic CII259-273
peptides were used: K264, representing the native non-
modified rat CII259-273 (rCII259-273) T cell epitope
(GIAGFKGEQGPKGEP), which have the same sequence in
human, bovine and chick type II collagen; HOK264 -
rCII259-273, containing (5R)-5-hydroxy-L-lysine at posi-
tion 264; GalOK264 - rCII259-273, modified by linkage of
b-D-galactopyranosyl residue to 5-hydroxy-L-lysine at
position 264. The K264 and HOK264 peptides were pro-
duced by Schafer-N (Copenhagen, Denmark). The
GalOK264 peptide was produced by Syngene (Bangalore,
India). Three other synthetic triple helical CII peptides
were used for evaluation of anti-CII antibody fine specifi-
city: C1, corresponding to CII amino acid sequence from
position 358-369 (CII358-369; GARGLTGRPGDA), U1,
corresponding to CII494-504 (GLVGPRGERGF), and J1
that represents CII551-564 (GERGAAGIAGPK). The
synthesis of these CII peptides has been previously
described [14]. Concanavalin A (ConA) was purchased
from Sigma-Aldrich (Munich, Germany), dissolved in PBS,
sterile filtered and stored at -20°C until use.
Animals
Two mouse strains were used in the present study both
on B10 genetic background - B10.Q and B10.DR4.Ncf1*/*.
The line B10.Q was initially provided by J. Klein (Tübin-
gen, Germany) and maintained for more than two dec-
ades at the animal facility at the section for Medical
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Inflammation Research (Lund University, Sweden). The
strain B10.DR4.Ncf1*/* was generated by a cross between
the B10.DR4 strain (transgenic mice that co-express
HLA-DR4 and human CD4 receptor [20]) and the B10.Q
Ncf1*/* (a B10.Q strain with a mutation in the Ncf1 gene,
leading to reduced reactive oxygen species production by
the NOX2 phagocyte complex [21]). The resulting gen-
eration was intercrossed in order to yield homozygous
DR4/humanCD4/H-2-/- individuals with a mutation in
the Ncf1 gene - the strain denoted as B10.DR4.Ncf1*/*.
The animals were kept under standard conditions - con-
trolled temperature, light and food regimen. All mice
used for experiments were eight-to-twelve-weeks old, age
and sex matched. Lund-Malmö laboratory animal ethics
committee approved the conducted animal research.
CIA induction and assessment
CIA was induced by immunization with 100 μ g of rat
CII or human CII emulsified with 100 μ l complete
Freund’s adjuvant (CFA; Difco, Detroit, MI, USA). Three
weeks postimmunization the animals were boosted with
50 μ g rCII or huCII emulsified with 50 μ l incomplete
Freund’s adjuvant (IFA; Difco). Evaluation of CIA was
initiated two weeks after the primary immunization and
the animals were examined two to three times per week.
Disease manifestations were assessed using 60-point sys-
tem with a maximal score of 15 points per paw [22].
T cell in vitro assay
At day 15, 35, 50 and 65 after primary immunization
five to ten mice were sacrificed; inguinal lymph nodes
were isolated and passed through a 25-μ m nylon cell
strainer (BD Discovery Labware, Franklin Lakes, NJ,
USA). Single cell suspensions were washed twice with
DPBS (Gibco, Life Technologies, Grand Island, NY,
USA) and restimulated with CII259-273 peptides, conA
and rCII or huCII. The cells were cultured in 96-well
plates (Nalge Nunc International; Thermo Fisher Scien-
tific, Rochester, NY, USA) for 96 h in 200 μ l Dulbecco’s
modified Eagle medium (DMEM; Gibco) supplemented
with 10% heat-inactivated fetal calf serum (FCS; Gibco)
and antibiotics (100 IU/ml penicillin and 100 μ g/ml
streptomycin). At the end of the incubation period 150
μ l of the culture medium from each sample well were
collected and frozen at -20°C until use. All samples
were plated in triplicates.
Cytokine ELISA
The collected culture medium samples were used to
determine interferon-g (IFN-g) levels by sandwich ELISA.
Ninety-six-well ELISA plates (Costar #3590; Corning Life
Sciences, MA, USA) were coated with 50 μ l anti-mouse
IFN-g antibody (5 μ g/ml, clone R46-A2; Mabtech AB,
Stockholm, Sweden) for 2 h at room temperature (RT)
or overnight at 4°C. The plates were then washed
with buffer and unspecific binding was blocked by 30
min incubation with 100 μ l/well 2% solution of non-fat
dry milk. After that, the plates were washed again and
incubated for 2 h at RT with 50 μ l culture medium from
in vitro restimulated T cells. At the end of the incubation
period washing was performed, 50 μ l biotinylated anti-
mouse IFN-g antibody (1 μ g/ml, clone AN18; Mabtech
AB) was added to each sample well and incubated for 1 h
at RT. After extensive washing Eu3+-labeled streptavidin
was added to the plates and IFN-g level in the samples
was detected on a Wallac Victor 1420 multilabel counter
(PerkinElmer, Waltham MA, USA) using the dissocia-
tion-enhanced lanthanide fluoroimmunoassay (DEL-
FIA™) system (PerkinElmer). Recombinant mouse IFN-g
or standardized supernatant from conA-stimulated sple-
nocytes were added to each ELISA plate as a positive
control and standard.
Anti-CII antibody measurement
Blood samples were taken from all experimental animals
at day 15, 35, 50 and 65 after the primary immunization.
Following centrifugation (6500 rpm for 20 min), serum
was isolated from all samples, diluted in PBS (serum/PBS -
1/10 ratio) and stored at -20°C until use. The level of anti-
CII antibodies in the samples was evaluated by ELISA.
In brief, 96-well Costar plates (Corning) were coated over-
night at 4°C with 10 μ g/ml phosphate solution of rCII or
huCII. The plates were then washed and blocked for
30 min at RT using 2% non-fat milk solution. Following
extensive washing, serum samples in serial dilutions were
added to the plates and incubated for 2 h at RT. The
plates were then washed and incubated with 1 μ g/ml
solution of horseradish peroxidase (HRP)-conjugated anti-
mouse immunoglobulin G (IgG) (heavy + light chain) anti-
body (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) for 1 h at RT. After extensive washing,
binding of anti-CII antibodies was revealed by the 2,2’-
azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)
system (Roche Diagnostics, Basel, Switzerland) and 405
nm-wavelength absorbance was detected using the Wallac
Victor 1420 counter (PerkinElmer). Pooled polyclonal
mouse serum with known anti-CII antibody concentration
was included to each test plate and served as a positive
control and standard.
For detection of epitope-specific anti-CII antibodies,
Costar plates #3590 (Corning Life Sciences) were coated
for 2 h at RT with 5 μ g/ml solution of synthetic triple-
helical peptides (C1, U1 and J1). The subsequent steps of
the assay are equivalent to the total anti-CII IgG ELISA,
described in the previous paragraph. The levels of epitope-
specific antibodies were determined using biotinylated
anti-mouse IgG  chain antibody (clone 187.1, incubated
on the plates for 1 h at RT in 1 μ g/ml concentration).
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Detection of specific binding was carried out using Eu3
+-labeled streptavidin and the DELFIA™ system (Perki-
nElmer) according to manufacturer’s recommendations.
Purified monoclonal antibodies to the three CII epitopes
were used as a positive control and standard on all plates.
Results
CIA development in B10.Q and B10 DR4-transgenic mice
CIA was induced in order to compare arthritis develop-
ment between the B10.Q strain and the DR4-transgenic
mice and relate it to CII-specific immune responses at cer-
tain stages of disease. The strain B10.DR4 that co-
expressed human CD4 and HLA-DRB*0401 and lacked
endogenous expression of mouse MHC II molecules was
resistant to CIA [23]. However, introducing a point muta-
tion in the Ncf1 gene (yielding the strain B10.DR4.Ncf1*/*)
led to susceptibility to arthritis [23]. The Ncf1 mutation
results in expression of truncated Ncf1/p47phox protein
that leads to reduced capacity for production of reactive
oxygen species by the phagocytic NADPH complex [21].
Therefore, the B10.DR4.Ncf1*/* is a more arthritis-suscep-
tible DR4-expressing CIA model and individuals from this
strain were used for the experiments presented in the cur-
rent study.
B10.Q and B10.DR4.Ncf1*/* mice were immunized with
rCII and visual score of CIA development was conducted
two to three times weekly until day 65 postimmunization.
Compared to B10.Q mice, the disease onset in DR4-
transgenics was observed at a later time point (Table 1,
Figure 1). Arthritic mice from both strains demonstrated
relatively similar mean disease severity at the four time
points chosen for evaluation of CII-specific immune
responses. B10.DR4.Ncf1*/* mice displayed slightly lower
disease incidence compared to B10.Q mice.
Longitudinal analysis of CII-specific T cell response in
B10.Q and B10.DR4.Ncf1*/* mice
To determine the CII-specific T cell response single cell
suspensions from inguinal lymph nodes were restimulated
in vitro with non-modified CII259-273 peptide (denoted
as K264), hydroxylated CII259-273 (HOK264) and glyco-
sylated CII259-273 peptide (GalOK264). Only peptides
with modified lysine at position 264 were used because
it was previously shown that this is the key amino acid
residue for CII-specific T cell recognition in H-2q and
HLA-DR4 mouse models [23,24]. Samples from B10.Q
and B10.DR4.Ncf1*/* mice were collected at four time
points after CIA induction: day 15, day 35, day 50 and day
65, all of them corresponding to different stage of disease
development. T cell activation in response to the CII pep-
tides was ascertained by detection of Th1-specific IFN-g
levels in the culture medium following restimulation. It is
known that other T cell subpopulations, that is, IL-17-
secreting T cells [25], are also present during CIA. We
recently detected Th17 cells in B10.DR4.Ncf1*/* mice [23],
and showed that their specificity to CII259-273 is mainly
to the unmodified epitope. However, our present study
was concentrated on the Th1 cell subtype, measuring IFN-
g levels, because CIA is generally considered as a Th1-
mediated disease [26] and susceptibility to CIA is asso-
ciated with certain MHC II allotype.
Figure 2 illustrates the results from the measurement
of CII-specific T cell responses. Confirming previous
findings [23,27], the data clearly shows that in the B10.
Q strain the glycosylated form of CII259-273
(GalOK264) is immunodominant while in B10.DR4.
Ncf1*/* mice immunodominant is the non-modified epi-
tope (K264) and also the hydroxylated form of the epi-
tope (HOK264). The main reason for this difference is
that the response to the non-modified and the hydroxy-
lated peptide is dramatically enhanced in the DR4 mice.
The response to the GalOK264 peptide on the other
hand is also increased at the established disease phase
or in arthritic mice.
Nevertheless, the T cell response to the immunodomi-
nant epitope in both strains was maintained during all
stages of CIA - at all studied CIA time points B10.Q
mice responded strongest against GalOK264 while B10.
DR4.Ncf1*/* strain responded strongest against K264 and
HOK264. We observed elevated level of recognition of
GalOK264 in B10.DR4.Ncf1*/* at day 50 postimmuniza-
tion but still the magnitude of this response was signifi-
cantly lower compared to K264 and HOK264. On the
other hand, B10.Q mice displayed T cell response to the
non-modified CII259-273 epitope during the early stage
of CIA development (day 15 postimmunization) while
the recognition of HOK264 was insignificant. However,
at the later time points (day 35, day 50, day 65) of dis-
ease development we detected higher response to the
hydroxylated form of CII259-273. This tendency is













% Incidence (day 35
arthritic vs. total
numberof mice)
% Incidence (day 50
arthritic vs. total
number of mice)
% Incidence (day 65
arthritic vs. total
numberof mice)
B10.Q 28 ± 3 13.4 ± 1.9 19.4 ± 2.2 14.1 ± 1.5 55 (11/20) 70 (14/20) 90 (18/20)
B10.DR4. Ncf1*/* 32 ± 1 16.4 ± 6 21 ± 5.6 9.8 ± 3.3 44.4 (8/18) 69.2 (9/13) 71.4 (5/7)
†Data represent mean values ± SE and include only arthritic animals.
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markedly pronounced on day 35 and day 65 postimmuni-
zation when we could not find significant difference
between the response to HOK264 and the response to the
immunodominant GalOK264 epitope. This result suggests
that T cell recognition of HOK264 in B10.Q mice tends to
correspond to manifestation of clinical signs of arthritis
while K264-specific T cells could play a role in the initial
phase of disease. In general, the level of CII-specific T cell
Figure 1 CIA disease course in B10.Q and B10.DR4.Ncf1*/* mice*. Experimental animals were immunized with 100 μ g rCII in CFA (day 0)
and three weeks later received a booster injection of 50 μ g rCII in IFA (day 21 postimmunization). CIA severity and incidence were evaluated
two to three times weekly until the end of experiment (day 65 postimmunization). (A) Mean arthritis score in B10.Q (n = 10) and B10.DR4.Ncf1*/*
mice (n = 7). Data are presented as mean ± SE and include both arthritic and healthy animals. (B) CIA incidence in B10.Q and B10.DR4.Ncf1*/*
mice. * Data represent CIA assessment only in mice examined until the end of experiment. CIA data from mice killed for in vitro T cell assays are
included in Table 1. CIA, collagen-induced arthritis; IFA, incomplete Freund’s adjuvant; rCII, rat collagen type II.
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activation in B10.Q mice showed tendency for correlation
with disease clinical score - the lowest magnitude of
response to CII259-273 was observed at day 15 when
there were no visible signs of arthritis but the level of CII-
specific T cell activation increased dramatically at the time
points when arthritis symptoms are evident. Interestingly,
this was not the case with B10.DR4.Ncf1*/* strain
(Figure 2, A). At the initial phase of disease (day 15 post-
immunization) we detected a strong IFN-g response
against K264 and HOK264 while at day 35 postimmuniza-
tion the level of IFN-g secretion following restimulation
with K264 and HOK264 peptides was lower. Fifty days
after CII immunization when most experimental animals
showed the highest CIA severity, we detected also the
highest level of IFN-g concentration in response to
CII259-273. And expectedly, at day 65 postimmunization
the magnitude of CII-specific T cell responses decreased
in line with the slightly reduced CIA severity (Table 1,
Figure 1, A).
Longitudinal analysis of CII-directed humoral response in
B10.Q and B10.DR4.Ncf1*/* mice
CIA development depends on both T and B cell responses.
Thus, together with CII-specific T cell recognition we ana-
lyzed also anti-CII antibody levels during different stages of
CIA. Concentration of total anti-CII IgG antibodies in B10.
Q and B10.DR4.Ncf1*/* mice was measured at four time
points during CIA (day 15, day 35, day 50, day 65 postim-
munization). Overall, antibody titers in DR4-transgenic
mice showed a tendency for correlation with CIA develop-
ment (Figure 3, A). Significant level of anti-CII IgG was
detected already at day 15 following immunization preced-
ing manifestation of disease visual symptoms. At day 35,
when around 40% of the experimental animals displayed
clinical signs of CIA, anti-CII antibodies titer increased.
The highest concentration of CII-specific antibodies was
measured at day 50 (established CIA) - the stage when the
majority of the mice were sick, many of them suffering
severe arthritis. At the end of the experiment, day 65
Figure 2 T cell specificity to the CII259-273 epitope and its posttranslationally modified forms. B10.Q and B10.DR4.Ncf1*/* mice were
immunized with 100 μ g CII in CFA (day 0) and boosted 21 days later with 50 μ g CII in IFA. Five to ten mice per group were sacrificed at day
15, 35, 50 and 65 postimmunization. Single cell suspensions from collected inguinal lymph nodes were incubated in vitro with collagen peptides
or (conA) for 96 h. Culture supernatant was then used for measurement of INF-g content. (A) T cell recall response in B10.DR4.Ncf1*/* strain. The
symbol ‘*’ marks responses that are significantly higher than the GalOK264 response. *, P <.05; **, P <.01; ***, P <.001. Mean IFN-g values for the
conA stimulated positive control: d. 15 - 10.276 ± 0.899 ng/ml; d. 35 - 4.386 ± 0.269 ng/ml; d. 50 - 15.915 ± 1.349 ng/ml; d. 65 - 7.996 ± 1 ng/ml.
(B) CII-specific T cell response in B10.Q mouse strain. The symbol ‘†’ marks significantly lower responses compared to GalOK264 response. †, P
<.05; ††, P <.01. Mean IFN-g values of the positive control: d. 15 - 1.927 ± 0.321 ng/ml; d. 35 - 7.004 ± 0.231 ng/ml; d. 50 - 4.569 ± 0.631 ng/ml;
d. 65 - 2.4 ± 0.3 ng/ml. Background values (IFN-g levels secreted by cells cultured in standard medium without CII peptides or conA) are
subtracted from the presented data. All data represent mean ± SE of triplicates. CFA, complete Freund’s adjuvant; con A, concanavalin A; CII,
collagen type II; IFA, incomplete Freund’s adjuvant; IFN, interferon.
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postimmunization, antibody concentration was still sus-
tained but decreased in line with reduced CIA severity in
most of the experimental animals. Compared to B10.DR4.
Ncf1*/* mice, the B10.Q strain displayed higher serum titers
of anti-CII antibodies (Figure 3, B). Again, elevated anti-
body concentration was detected before disease onset (day
15 postimmunization) and it increased further together
with the manifestation of clinical signs of CIA (day 35 and
day 50). Interestingly, B10.Q mice showed the highest anti-
CII antibodies level at the end of experiment (day 65 post-
immunization). Presumably, this result could be due to the
high incidence of sick animals (90% in total, Table 1) and
also more severe disease in comparison with B10.DR4.
Ncf1*/* (Table 1, Figure 1, A).
Together with total anti-CII antibody titers, epitope-
specific antibody levels were evaluated. In CIA and also
Figure 3 CII-specific antibody response at different time points after CIA induction. Blood samples were taken from B10.Q and B10.DR4.
Ncf1*/* mice at four time points after rCII immunization (day 15, 35, 50 and 65). Extracted sera were used to assess the levels of anti-CII
antibodies, anti-C1, anti-U1 and anti-J1 epitope-specific antibodies. (A) Total anti-CII antibody concentration in sera of B10.DR4.Ncf1*/* mice
(number of animals per group: day 15 - n = 22, day 35 - n = 16, day 50 - n = 10, day 65 - n = 5). (B) Total anti-CII antibodies concentration in
B10.Q mice (n = 20 per each time point). (C) Anti-C1, anti-U1 and anti-J1 antibody levels, measured in B10.DR4.Ncf1*/* mouse strain (number of
animals per group: day 15 - n = 22, day 35 - n = 16, day 50 - n = 10, day 65 - n = 5). (D) Levels of anti-CII epitopes (C1, U1, J1) antibodies in
B10.Q mice (n = 20 per each time point). Results indicate mean ± SE. CIA, collagen-induced arthritis; CII, collagen type II.
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in RA CII-specific antibodies recognize and bind certain
conserved epitopes [14-16]. To determine anti-CII anti-
bodies fine specificity in a longitudinal manner and
compare it between B10.Q and B10.DR4.Ncf1*/* mice,
we measured anti-U1, anti-C1 and anti-J1 antibody titers
at the four chosen time points during CIA development.
As shown on Figure 3 (C, D) the majority of epitope-
specific anti-CII antibodies recognized the C1 epitope.
This specificity dominated during all stages of CIA
development in both experimental strains. The highest
levels of anti-C1 antibodies were detected on day 35 and
day 50 postimmunization in line with manifestation of
clinical signs of CIA. In addition, B10.Q mice showed a
low response to U1 and J1 epitopes that was most pro-
minent at the time points when arthritis symptoms are
present. The B10.DR4.Ncf1*/* mice exhibited a promi-
nent response also to U1 epitope, while recognition of
J1 epitope was negligible in both strains.
Arthritic B10.Q and B10.DR4.Ncf1*/* mice display CII-
specific immune responses with significantly higher
magnitude
During a standard CIA experiment with B10.Q and B10.
DR4.Ncf1*/* mice disease symptoms are well pronounced
around day 50 postimmunization. Usually, the animals
that have not shown CIA clinical signs until this time
point do not develop disease. Therefore, we chose this
stage of the experiment for comparison of CII-specific
immune responses between arthritic and healthy B10.Q
and B10.DR4.Ncf1*/* individuals. The results, illustrated
in Figure 4, show a clear tendency for significantly stron-
ger CII-directed reactivity in sick animals in both strains.
We even found markedly increased T cell response to
GalOK264 peptide in B10.DR4.Ncf1*/* arthritic mice
(Figure 4, A). This data suggest a certain role, although
not a dominant one, for the glycosylated CII-259-273 epi-
tope in CIA in the DR4-transgenic model. In the case of
B10.Q mice, significant difference between arthritic and
healthy animals was present only for the T cell reactivity
to GalOK264 peptide (Figure 4, B). When looking at the
humoral response, we could see a marked contrast
between arthritic and non-arthritic animals in both
strains on the level of total anti-CII antibodies (Figure 4,
C and 4D), as well as anti-C1 antibodies (Figure 4, E and
4F). B10.DR4.Ncf1*/* arthritic mice had also significantly
higher levels of anti-U1 and anti-J1 antibodies.
T cell response fine specificity in B10.DR4.Ncf1*/* mice is
not dependent on the glycosylation level of
administrated CII
The present study demonstrates a remarkable difference
between the B10.Q and the B10.DR4.Ncf1*/* model on
the level of CII-directed T cell specificity. B10.Q T cells
generally react against the glycosylated CII259-273
epitope, while T cells in DR4-transgenics predominantly
recognize the native and hydroxylated CII259-273 epi-
tope. One possible explanation for this contrast could
be the presence of second lysine residue at position 270
in CII259-273 that could play a major role in T cell
recognition in the context of DR4 restriction. However,
our previous studies have shown that this is not the
case and that K264 is the main T cell receptor interac-
tion point [23]. Another reason could be the collagen
type II, used for immunization of experimental animals
and its level of glycosylation. If the immunizing CII dis-
plays higher extent of glycosylation then it could induce
a stronger GalOK264 response. The rCII that is routi-
nely used for immunization is derived from Swarm
chondrosarcoma - a tumor cell line that produces col-
lagen molecules with both hydroxylated and glycosylated
residues [28]. In contrast, CII derived from normal carti-
lage is more uniformly glycosylated as determined in
rats and humans [28]. Therefore, to test whether the
glycosylation extent of CII could influence T cell reac-
tivity, we immunized B10DR4.Ncf1*/* mice with huCII
and evaluated CII-specific immune responses during
CIA. The results from this experiment, however, con-
firmed the immunodominant status of K264 and
HOK264 for CII-specific T cell recognition in DR4-
transgenic mice (Figure 5, A). The only stage of CIA
development when we could see significant GalOK264
recognition was day 50 postimmunization, again, sug-
gesting cartilage immune recognition leading to epitope
spreading in line with the peak of disease severity. The
magnitude of T cell response also followed the same
trend as the B10.DR4.Ncf1*/* mice immunized with rCII
- strong T cell reaction at day 15 and 50 postimmuniza-
tion, and lower responses at day 35 and 65. Expectedly,
total anti-CII antibody responses were also similar and
anti-C1 antibodies predominated the epitope-specific
response (Figure 5, B and C).
Discussion
In both RA and CIA joint cartilage is affected by mas-
sive inflammation that drives destruction of the tissue.
Immune responses against CII, the main synovial com-
ponent, take part in this process. During arthritis, CII is
degraded to small peptides that are presented to T cells.
Previously, we identified the immunodominant epitope
CII259-273 [10] in which the K264 residue plays a key
role for CII-specific T cell recognition in mouse models
expressing either Aq or HLA-DR4 MHC II molecules
[23,24]. Furthermore, we have demonstrated that K264
is glycosylated in normal human and rat joint cartilage
while in arthritic cartilage the CII259-273 epitope is pre-
sent in both non-modified and glycosylated form (K264
and GalOK264, respectively) [28]. This finding raised an
important question for the role of K264 glycosylation/
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Figure 4 Comparison of CII-specific T cell and antibody responses in arthritic vs. nonarthritic animals (day 50 postimmunization).
(A) IFN-g recall response to CII259-273 peptides, measured in sick and healthy B10.DR4.Ncf1*/* mice. Mean positive control values: arthritic mice -
17.294 ± 1.274 ng/ml; nonarthritic animals - 14.696 ± 2.266 ng/ml. (B) CII-specific T cells response in arthritic vs. nonarthritic B10.Q mice. Mean
IFN-g values for the positive control: arthritic animals - 5.199 ± 0.819 ng/ml; nonarthritic mice - 3.624 ± 0.903 ng/ml. Background INF-g levels
were subtracted from all T cell responses data. (C) and (D) Anti-CII antibody concentrations in arthritic vs. nonarthritic B10.DR4.Ncf1*/* and B10.Q
mice, respectively. (E), (F) Levels of antibodies, specific to C1, U1 and J1 CII epitopes in B10.DR4.Ncf1*/* and B10.Q sick and healthy mice,
respectively. All data display mean ± SE. *, P <.05; **, P <.01; ***, P <.001. CII, collagen type II; IFN, interferon.
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deglycosylation state in arthritis development. Therefore,
the present study aimed to investigate CII-specific T cell
responses at different time points of CIA in order to
clarify whether there is a shift in T cell recognition of
CII259-273 and its posttranslationally modified forms
during disease development. We have chosen to focus
on Th1 response in this study as CII-specific T cell
response in CIA is dominated by Th1 cells [26], which
produce IL-2 and IFN-g and could thus drive the pro-
duction of complement-fixing CII-specific IgG2a, an
Figure 5 T cell specificity to the CII259-273 epitope and its posttransationally modified forms in B10.DR4.Ncf1*/* mice following
immunization with huCII. Experimental animals were immunized with 100 μ g huCII emulsified in CFA at day 0. Twenty-one days later the
mice received a booster immunization of 50 μ g huCII in IFA. At four particular time points after immunization (day 15, 35, 50, 65) five mice per
group were sacrificed and inguinal lymph nodes were harvested for further analysis. (A) T cell recall responses in huCII-immunized B10.DR4.
Ncf1*/* mice following in vitro restimulation with CII259-273 peptides. Mean IFN-g values for the conA positive control at each time point: d. 15 -
2.884 ± 0.313 ng/ml; d. 35 - 2.137 ± 0.485 ng/ml; d. 50 - 4.732 ± 0.53 ng/ml; d. 65 - 4.632 ± 0.291 ng/ml. Responses that are significantly higher
than the GalOK264 response were marked with ‘*’. Background IFN-g values are subtracted from the presented data. (B) Total CII-specific
antibody levels in B10.DR4.Ncf1*/* mice immunized with huCII. (C) CII epitope-specific antibody levels B10.DR4.Ncf1*/* mice immunized with
huCII. Data designate mean ± SE. *, P <.05; **, P <.01; ***, P <.001. CFA, complete Freund’s adjuvant; con A, concanavalin A; (hu)CII, (human)
collagen type II; IFA, incomplete Freund’s adjuvant; IFN, interferon.
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important component in the pathogenesis of CIA [29].
Interestingly, no shift in T cell recognition was observed
during the phases investigated. In general, B10.DR4.Ncf1*/*
mice displayed dominant T cell reactivity to the non-mod-
ified CII259-273 and also to the hydroxylated form of the
epitope. The dominant B10.Q T cell response was directed
against the glycosylated CII259-273 epitope. An exception
to this rule was seen only at the initial stage of CIA in
B10.Q mice when a relatively equal T cell reactivity to
non-modified CII259-273 and to the glycosylated peptide
was detected. One possible reason for this discrepancy
could be the CII used for immunization. This protein con-
tains both non-modified and glycosylated CII259-273 epi-
topes since it is extracted from Swarm chondrosarcoma,
which do not uniformly glycosylate the CII molecule [28].
Thus, it is to be expected that the mice would initially
react against both glycosylated and non-modified epitope
since following immunization both epitopes are picked
up from the CII molecule and presented by T cells.
Such tendency, although not that strong, is also evident
in B10.DR4.Ncf1*/* mice where, in addition to the
strong K264 and HOK264 response, we detected certain
level of response to the GalOK264 peptide. Moreover,
previous studies on T cell responses at an earlier time
point following immunization showed even more pro-
nounced response against the glycosylated epitope in
DR4 mice (Dzhambazov et al., unpublished data).
Therefore, we assume that presentation and recognition
of both non-modified and glycosylated CII259-273 fol-
lowing immunization occurs earlier in DR4-transgenic
mice compared to B10.Q mice. That would explain also
the very high magnitude of response to K264 and
HOK264 epitopes detected in B10.DR4.Ncf1*/* mice
already at day 15 postimmunization.
The lack of uniform glycosylation level of Swarm-
derived rCII could also be the reason for stronger T cell
response to non-modified CII259-273 epitope in B10.DR4.
Ncf1*/* mice. To test this hypothesis, a group of DR4 mice
with human CII was immunized with a protein extracted
from normal human cartilage that is known to contain
exclusively glycosylated CII259-273 [28]. The results, how-
ever, could not clearly confirm our hypothesis. Again, we
detected a dominant T cell response to K264 and
HOK264 epitopes. The only time point when we identified
a significant GalOK264 response was day 50 postimmuni-
zation. At this time point, we detected a higher reactivity
to the glycosylated epitope also in mice immunized with
Swarm chondrosarcoma-derived rCII. During this stage of
disease, the stronger response to the GalOK264 peptide
could be attributed to epitope spreading in T cell specifi-
city due to the acute inflammation process and developed
immunity to the endogenous CII. Similarly, certain
response to the other forms of CII259-273 epitope, in
addition to the immunodominant one, was detected also
in B10.Q mice at later time points of CIA (day 35, day 50,
day 65).
The T cell responses in RA patients carrying HLA-
DRB*04 alleles show a diverse pattern of CII259-273
epitope recognition, that is, toward both non-modified
and glycosylated CII259-273; only few patients exclu-
sively responded to K264 but most of them to GalOK264
[5,6]. A longitudinal analysis of CII-specific T cell
responses showed a consistent reactivity but variable
magnitude and specificity of the response over time [6].
Concerning the magnitude of T cell reactivity our results
are in line with the RA patients’ data since we could not
see a correlation between disease visible signs (disease
severity) and the level of IFN-g secreted in response to
CII259-273 stimulation in DR4-expressing mice. Also, in
concordance with the human patients’ data our results
demonstrate significantly higher CII responses in
arthritic compared to healthy individuals. However, when
looking at T cell response specificity the results from RA
patients are in contrast with our findings in DR4-trans-
genic mice where we could demonstrate a very strong
response to the K264 epitope. This discrepancy raises an
important question - whether the DR4-transgenic mouse
model could accurately resemble the human disease set-
ting and whether there is a need for improving the huma-
nized model. Indeed, the standard transgenic technology
implies insertion of an unknown number of transgene
copies into the mouse genome and also the site/sites of
transgene insertion is/are uncertain, which in turn could
affect the physiological expression of the transgene itself.
Interestingly, the more physiologic Aq mouse model
resembles the CII response in RA better than the more
artificial but humanized DR4 mouse.
CII-specific immunity in CIA and RA include both
T and B cell responses. Thus, we included to our studies
evaluation of anti-CII antibody levels during CIA. The
longitudinal analysis of total CII-specific titers in B10.
DR4.Ncf1*/* showed a trend for correlation with disease
severity but in B10.Q mice we detected a different pat-
tern of antibody levels during CIA with day 65 (about the
end of the CIA acute phase characterized by slightly
decreased disease severity) showing the highest anti-CII
IgG concentration. It is likely that the high antibody
levels at day 65 is triggered by an endogenous response
to cartilage CII and could precede and contribute to
another peak of disease severity at a later time point. On
the other hand, it has been shown that high anti-CII anti-
body titers do not exclusively lead to more severe disease
[30]. The total CII-specific levels are polyclonal and
include clones that do not contribute to arthritis develop-
ment [14]. Thereby, an epitope-specific antibody
response will be expected to show a better tendency for
correlation with disease. Three dominant conserved CII
epitopes - C1, U1, and the J1 epitope, can be recognized
Batsalova et al. Arthritis Research & Therapy 2012, 14:R237
http://arthritis-research.com/content/14/6/R237
Page 11 of 13
both in CIA and RA [14,15]. Our experiments included
evaluation of epitope-specific antibody responses in B10.
Q and B10.DR4.Ncf1*/* mice and indicated a dominant
response to the C1 epitope during the different phases of
CIA. Anti-C1 antibody levels showed a positive relation
to disease clinical score - the highest titers were detected
during acute stages of CIA while at day 65 postimmuni-
zation C1-specific antibodies decreased in both mouse
models. B10.DR4.Ncf1*/* mice showed very low level of
recognition of J1 epitope but a sustained response to U1
epitope. Interestingly, anti-U1 antibody levels were rela-
tively constant at all studied CIA time points. In fact, pre-
vious studies on U1-specific monoclonal antibody have
shown that it binds and destabilizes cartilage indepen-
dent of inflammation [31]. It is likely that this mechanism
of action is the reason for a lack of increase of U1-speci-
fic antibody titers at the acute stage of disease. However,
additional experiments are needed in order to clarify
whether this result could be due to non-optimal physio-
logical setting in the transgenic model. This study was
limited to three immunodominant CII epitopes. Despite
the lack of epitope shift during the various disease phases
investigated one cannot exclude involvement of addi-
tional CII epitopes during different stages of CIA, an
ongoing study (Lindh et al., unpublished data).
Conclusions
The present study provides important evaluation of CII-
specific immune responses at different phases during
CIA development as well as a comparative analysis
between two CIA mouse models. We show evidence for
dominant and specific recognition of CII T and B cell
epitopes during CIA in both studied mouse strains. We
did not observe a shift in CII epitope specificity at differ-
ent stages of disease development. A trend for epitope
spreading during acute stage of CIA was evident in both
B10.Q and B10.DR4.Ncf1*/* mice. Significant differences
in CII T cell and antibody specificities between the two
mouse models were indicated. Importantly, we also high-
light a need for improved humanized B10.DR4 mouse
model as the transgenic expression of human MHC II
leads to a skewing of the T cell response towards the
non-glycosylated form of the CII259-273 epitope.
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